Study In Airway Physiology In Children SERETIDE DISKUS ® Inhlaer and FLIXOTIDE® Inhaler Are Trademarks of GSK Group of Companies.
Phase 4
Completed
- Conditions
- Asthma
- Interventions
- Drug: Salmeterol/fluticasone propionate
- Registration Number
- NCT00169546
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
Comparison of two asthma treatments by lung function measures.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 64
Inclusion Criteria
Not provided
Exclusion Criteria
- 3 or more courses of oral steroids in last 12 months.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm 1 Salmeterol/fluticasone propionate - Arm 1 Fluticasone propionate -
- Primary Outcome Measures
Name Time Method sRAW (k.Pa.s) measured before the study medication dose at the end of treatment (week 6)
- Secondary Outcome Measures
Name Time Method sRAW measured pre-dose at Week 3. sRAW measured 48 hours after last study medication dose. % symptom-free days over Weeks 1-6. % symptom-free nights over Weeks 1-6. Type and frequency of adverse events.
Trial Locations
- Locations (1)
GSK Investigational Site
🇬🇧Manchester, Lancashire, United Kingdom